Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions

Featuring 40% more content, this new edition captures the trends and major achievements in the art of making chiral chemical compounds on an industrial scale by assembling contributions from world leaders in the respective areas to provide a compact and qualified insight into this field. A plethora of case studies are included on the development of as many large–scale enantioselective processes as possible, showing the "real life" of this challenging field. As a result, this ready reference and handbook collates first–hand and valuable information within a context where it can be easily found.
The high–quality contributions illustrate the relevant environments and situations, such as time pressure, how the catalytic step fits into the over–all synthesis, or competition with other synthetic approaches, as well as the typical problems encountered in the various phases, including finding/developing the catalyst and optimization of the process or choice of equipment. Both successful and unsuccessful approaches to solve these problems are described.


Spis treści:
Chemoenzymatic Route to the Side Chain of Rosuvastatin
Application of Multiple Enzyme Systems for Chiral Alcohols Production
Whole Microbial Cell Process for Manufacturing Amino Acids, Dipeptides and Oligosaccharides by Enzyme Catalysts Coupling with Cofactor Regeneration
Biocatalytic Routes to the Large Scale Synthesis of Lotrafiban
Asymmetric Oxidation for the Production of Bicyclic Proline Peptidomimetics
Enzymatic C–C Bond Formation
Large–Scale Applications of Hydrolases in Biocatalytic Asymmetric Synthesis
Enzymatic Two Step Approach Towards a Chiral Intermediate on Pilot Scale for a Coagulation Factor Xa Inhibitor
An Efficient, Asymmetric Synthesis of Odanacatib, a Selective Inhibitor of Cathepsin K for the Treatment of Osteoporosis, Using an Enzyme Mediated Dynamic Kinetic Resolution
The Discovery and Implementati on of a Novel Catalytic Asymmetric Conjugate Addition Reaction in the Synthesis of Endothelin A Antagonist ABT–546
Scale–Up Studies in Asymmetric Transfer Hydrogenation
Ru–(Phosphine–Oxazoline) Complexes as Effective, Industrially Viable Catalysts for the Enantioselective Hydrogenation of Aryl Ketones
Chiral Lactones by Asymmetric Hydrogenation –
A Step Forward in (+)– Biotin Production
The Asymmetric Hydrogenation of an Alpha–Isopropyl–Cinnamic Acid, an Intermediate for the Blood–Pressure Lowering Drug Aliskiren
Commercialization of the Maruoka Catalyst
Development of Efficient Technical Processes for the Production of Enantiopure Amino Alcohols in Pharmaceutical Industry
The Kagan Oxidation –
Industrial Scale Asymmetric Sulfoxidations in the Synthesis of Two Related NK1/NK2 Antagonists
The Asymmetric Hydrogenation of Enones
Large Scale Application of Asymmetric Phase Transfer Catalysis for Amino Acid Synthesis
Crossing Over Hurdles in Large Scale Asymmetric Hydrogenation
Application of Phase Transfer Catalysis in the Asymmetric Synthesis of an Estrogen Receptor Beta Selective Agonist
Rh/Josiphos Catalyzed Ring Opening of Oxabicycles
Hydrogenations on Multi kg Scale
2,2′,5,5′–Tetramethyl–4,4′–bis(diphenylphosphino)–3,3′–bithiophene: A not well Known but very Efficient Chiral Ligand for Ru Catalyzed Asymmetric Hydrogenations on Multi–Kilos Scale
3+2 Addition Reaction and Diastereosel Reduction f Imine Both on Multi 10 kg Scale
Enantioselective Hydrogenation: Applications in Process R&D of Pharmaceuticals

Nota biograficzna:
Hans–Ulrich Blaser is chief technology officer at Solvias. He carried out his doctoral research with A. Eschenmoser at the Federal Institute of Technology (ETH) Zurich, where he received his PhD in 1971. Between 1971 and 1975 he held postdoctoral po sitions at the University of Chicago, Harvard University, and Monsanto. Over 20 years at the Ciba–Geigy Central Research Laboratories (1976–1996) he gained practical experience in R&D within the fine chemicals and pharmaceutical industry, which continued at Novartis (1996–1999). Dr. Blaser′s main interest is selective catalysis with an emphasis on enantioselective catalysts, and during his industrial career he has developed and implemented numerous catalytic routes for agrochemicals, pharmaceuticals and fine chemicals both as a project leader and section head.
Hans–Jurgen Federsel gained his PhD in organic chemistry from the Royal Institute of Technology in Stockholm, where he is now an Associate Professor. He is a renowned specialist in the field of process R&D, where he has spent his entire professional career, spanning a period of 30 years. Starting off as a bench chemist at what was formerly Astra, he has occupied positions both as line and project manager. After the merger with Zeneca, he was the Head of Projects Management before being appointed a Director of Science in Global Process R&D at the beginning of 2004, which also brought the title of Senior Principal Scientist. Dr. Federsel publishes in peer–reviewed journals and books and frequently lectures all over the world.